Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 6/20 | 0.54 |
| ▸ | NMUR1 | Q9HB89 | 6/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.51 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29871019 | 0.89 | NMUR2 (0.58) | NMUR2NMUR1OPRD1OPRM1EPHA2 | |
| SCHEMBL31052975 | 0.89 | NMUR2 (0.58) | NMUR2NMUR1OPRD1OPRM1EPHA2 | |
| SCHEMBL19220694 | 0.89 | OPRD1 (0.50) | OPRD1OPRM1OPRK1 | |
| SCHEMBL2194079 | 0.86 | OPRD1 (0.49) | OPRD1OPRM1OPRK1 | |
| SCHEMBL2053622 | 0.85 | OPRD1 (0.53) | NMUR2NMUR1OPRD1OPRM1EPHA2 | |
| SCHEMBL30393693 | 0.85 | OPRD1 (0.54) | OPRD1OPRM1OPRK1 | |
| SCHEMBL29610294 | 0.82 | OPRM1 (0.54) | OPRD1OPRM1OPRK1 | |
| SCHEMBL30198506 | 0.82 | NMUR2 (0.56) | NMUR2NMUR1OPRD1OPRM1EPHA2 | |
| SCHEMBL30148933 | 0.82 | BDKRB2 (0.58) | OPRD1OPRM1 | |
| SCHEMBL31467755 | 0.82 | OPRM1 (0.53) | OPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10376532-B2 | Methods of treating, reducing the incidence of, and/or preventing ischemic events | CHIESI FARMACEUTICI, S.P.A. (IT) | 2019-08-13 | — | — | US | disclosed |
| US-9925265-B2 | Methods of treating or preventing stent thrombosis | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-03-27 | — | — | US | disclosed |
| US-20110112030-A1 | METHODS OF TREATING OR PREVENTING STENT THROMBOSIS | THE MEDICINES COMPANY (US) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112030-A1 | METHODS OF TREATING OR PREVENTING STENT THROMBOSIS | SERPINC1, PLAT, HABP2 | NMUR2 1655/4885NMUR1 1136/4885OPRD1 3715/4885 |
| US-10376532-B2 | Methods of treating, reducing the incidence of, and/or preventing ischemic events | P2RY12, P2RY11, PTAFR | NMUR2 1118/4885NMUR1 924/4885OPRD1 3790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.